SCHEMBL3380293

SCHEMBL3380293

NC(=O)c1ccccc1-c1ccc2[nH]ncc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 11/20 0.59
AR P10275 1/20 0.56
TRPM8 Q7Z2W7 1/20 0.56
TGFBR1 P36897 1/20 0.55
CDK5 Q00535 3/20 0.55
CLK4 Q9HAZ1 3/20 0.55
DYRK1B Q9Y463 2/20 0.55
CLK2 P49760 2/20 0.55
GSK3B P49841 2/20 0.55
DYRK1A Q13627 2/20 0.55
DYRK3 O43781 1/20 0.55
CLK1 P49759 1/20 0.55
CLK3 P49761 1/20 0.55
CDK5R1 Q15078 1/20 0.55
DYRK2 Q92630 1/20 0.55
CDC7 O00311 2/20 0.49
DAPK3 O43293 2/20 0.49
MAP4K4 O95819 2/20 0.49
FGFR1 P11362 2/20 0.49
CSNK1A1 P48729 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29740965 0.89 BTK (0.59) TRPA1ARCDK5CLK4DYRK1B
SCHEMBL3378316 0.89 BTK (0.59) TRPA1ARCDK5CLK4DYRK1B
SCHEMBL11890140 0.84 TRPA1 (0.60) TRPA1ARTRPM8TGFBR1CDK5
SCHEMBL27810091 0.83 TRPA1 (0.66) TRPA1ARTRPM8TGFBR1CDK5
SCHEMBL17593702 0.81 PARP1 (0.47) TRPA1ARTGFBR1CDK5CLK4
SCHEMBL30627398 0.80 TGFBR1 (0.50) TRPA1ARTGFBR1CDK5CLK4
SCHEMBL7572389 0.80 TGFBR1 (0.50) TRPA1ARTGFBR1CDK5CLK4
SCHEMBL20509685 0.80 AR (0.53) TRPA1ARTGFBR1CDK5CLK4
SCHEMBL17593699 0.80 CCNC (0.50) TRPA1ARCDK5CLK4DYRK1B
SCHEMBL27663175 0.78 TRPA1 (0.68) TRPA1TRPM8TGFBR1CDK5CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 TRPA1 88/4885AR 1407/4885TRPM8 91/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 TRPA1 274/4885AR 385/4885TRPM8 198/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 TRPA1 88/4885AR 1407/4885TRPM8 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.